About Mission Therapeutics
Mission Therapeutics is a company based in Cambridge (United Kingdom) founded in 2011 by Stephen Philip Jackson, Theodora Harold, and Keith Menear.. Mission Therapeutics has raised $192.23 million across 9 funding rounds from investors including Roche, IP Group and The Michael J. Fox Foundation. The company has 45 employees as of December 31, 2021. Mission Therapeutics offers products and services including MTX325 and MTX652. Mission Therapeutics operates in a competitive market with competitors including Biogen, BridgeBio, Moderna, Denali Therapeutics and Spark Therapeutics, among others.
- Headquarter Cambridge, United Kingdom
- Employees 45 as on 31 Dec, 2021
- Founders Stephen Philip Jackson, Theodora Harold, Keith Menear
- Stage Minicorn
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Mission Therapeutics Limited
- Date of Incorporation 11 May, 2011
- Jurisdiction CAMBRIDGE
-
Annual Revenue
$1.46 M (USD)277as on Dec 31, 2016
-
Net Profit
$-78.9 M (USD)-538as on Dec 31, 2022
-
EBITDA
-
Total Equity Funding
$192.23 M (USD)
in 9 rounds
-
Latest Funding Round
$13.3 M (USD), Series D
Oct 15, 2025
-
Investors
Roche
& 12 more
-
Employee Count
45
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Mission Therapeutics
Mission Therapeutics offers a comprehensive portfolio of products and services, including MTX325 and MTX652. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Inhibits USP30 to treat Parkinson's and enhance cellular quality control.
Targets USP30 for heart failure and other mitochondrial diseases.
Unlock access to complete
Unlock access to complete
Unlock access to complete
Funding Insights of Mission Therapeutics
Mission Therapeutics has successfully raised a total of $192.23M across 9 strategic funding rounds. The most recent funding activity was a Series D round of $13.3 million completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 9
- Last Round Series D — $13.3M
-
First Round
First Round
(24 Aug 2011)
- Investors Count 13
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Oct, 2025 | Amount | Series D - Mission Therapeutics | Valuation | Pfizer Venture Investments , Sofinnova Partners |
|
| Jul, 2024 | Amount | Grant - Mission Therapeutics | Valuation |
investors |
|
| Mar, 2024 | Amount | Series D - Mission Therapeutics | Valuation | Rosetta Capital |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Mission Therapeutics
Mission Therapeutics has secured backing from 13 investors, including institutional and venture fund investors. Prominent investors backing the company include Roche, IP Group and The Michael J. Fox Foundation. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital is focused on healthcare by Pfizer's investment arm.
|
Founded Year | Domain | Location | |
|
Sofinnova Partners is focused on life sciences and healthcare investments.
|
Founded Year | Domain | Location | |
|
A biotechnology venture capital firm investing in innovative science.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Mission Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Mission Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Mission Therapeutics Comparisons
Competitors of Mission Therapeutics
Mission Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Biogen, BridgeBio, Moderna, Denali Therapeutics and Spark Therapeutics, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Therapies for neurodegenerative and immunology disorders are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for genetic diseases are developed through targeted interventions.
|
|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| domain | founded_year | HQ Location |
Gene therapies for rare diseases including retinal dystrophies are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Mission Therapeutics
Frequently Asked Questions about Mission Therapeutics
When was Mission Therapeutics founded?
Mission Therapeutics was founded in 2011.
Where is Mission Therapeutics located?
Mission Therapeutics is headquartered in Cambridge, United Kingdom. It is registered at Cambridge, Cambridgeshire, United Kingdom.
Who is the current CEO of Mission Therapeutics?
Anker Lundemose is the current CEO of Mission Therapeutics.
Is Mission Therapeutics a funded company?
Mission Therapeutics is a funded company, having raised a total of $192.23M across 9 funding rounds to date. The company's 1st funding round was a Series D of $32.24M, raised on Aug 24, 2011.
How many employees does Mission Therapeutics have?
As of Dec 31, 2021, the latest employee count at Mission Therapeutics is 45.
What is the annual revenue of Mission Therapeutics?
Annual revenue of Mission Therapeutics is $1.46M as on Dec 31, 2016.
What does Mission Therapeutics do?
Small molecule drugs that target deubiquitylating enzymes involved in the DNA damage response. It offers lead candidates MTX325 and MTX652 that aims to inhibit USP30, a DUB which can retard the essential cellular quality control process called mitophagy for the treatment of Parkinsons Disease, heart and kidney diseases, fibrosis, and rare mitochondria diseases.
Who are the top competitors of Mission Therapeutics?
Mission Therapeutics's top competitors include Moderna, Spark Therapeutics and BridgeBio.
What products or services does Mission Therapeutics offer?
Mission Therapeutics offers MTX325 and MTX652.
Who are Mission Therapeutics's investors?
Mission Therapeutics has 13 investors. Key investors include Roche, IP Group, The Michael J. Fox Foundation, Woodford Investment Management, and Imperial Innovations.
What is Mission Therapeutics's valuation?
The valuation of Mission Therapeutics is $130.38M as of Jan 2021.